Merck, as it prepares a new version of its cancer blockbuster Keytruda, gets a boost in its patent dispute with Halozyme ...

Alvotech (NASDAQ:ALVO) and Dr. Reddy’s Laboratories (NYSE:RDY) have entered into a collaboration and license agreement to ...

However, beneath this success lies a growing concern: the sustainability of this growth trajectory, particularly as ...

The former workers cited various reasons why they think Novo was cautious: its conservative culture and history of investing ...

By Deena Beasley (Reuters) -Gilead Sciences' Trodelvy in combination with Merck's blockbuster immunotherapy Keytruda lowered ...

Alvotech and Dr. Reddy's Laboratories Ltd., today announced that the companies have entered into a collaboration and license ...

The latest findings support the expectation that the combination therapy will become the new SOC in PD-L1-positive TNBC.

Dr. Reddy's and Alvotech have partnered to co-develop a biosimilar of Keytruda, Merck's $29.5 billion cancer drug, boosting ...

First pivotal Phase 3 trial to show superiority of KEYTRUDA plus a TROP2 antibody-drug conjugate, Trodelvy, versus standard of care in first-line metastatic TNBC “These results have the ...

Dr. Reddy's and Alvotech collaborate to develop biosimilar to Keytruda, enhancing oncology capabilities and global reach.

Alvotech and Dr Reddy’s Laboratories announced today they have entered a collaboration agreement to co-develop, manufacture ...

Dr. Reddy's Laboratories and Alvotech are collaborating to develop, manufacture, and commercialize a biosimilar version of ...